Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia

KİRMİZİ, Demet Aydogan; BASER, Emre; INANDİKLİOGLU, Nihal

doi:10.4274/haseki.galenos.2021.7101

Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia

Nihal Inandiklioglu, (Yozgat Bozok Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, Yozgat, Türkiye)

Emre Baser, (Yozgat Bozok Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Yozgat, Türkiye)

Demet Aydogan Kirmizi (Yozgat Bozok Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Yozgat, Türkiye)

Haseki Tıp Bülteni

2 0

Yıl: 2021 Cilt: 59 Sayı: 4 Sayfa Aralığı: 308 - 312 Metin Dili: İngilizce DOI: 10.4274/haseki.galenos.2021.7101 İndeks Tarihi: 04-11-2021

Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia

Öz:

Aim: Preeclampsia is a pregnancy-specific disease of unknown etiology. This study was planned to determine the place of asymmetricdimethylarginine (N, N-dimethylarginine, ADMA) and endothelial cell specific molecule-1 (ESM1, endocan) levels in etiology. The aim ofthis study was to determine ADMA and endocan levels in maternal and fetal umbilical cord serum of patients with preeclampsia andto evaluate them with clinical data.Methods: This case-control study was conducted between June and December 2020. The clinical and demographic characteristics ofthe participants were evaluated in the department of obstetrics and gynecology. Thirty-tree women with preeclampsia and 55 healthywomen in the same age group were included in our study. Serum ADMA and endocan values were determined by the ELISA method.Results: Maternal and umbilical cord ADMA levels in the preeclampsia group were statistically significantly higher than the controlgroup (p=0.001, p=0.001, respectively). Likewise, the levels of the umbilical cord and maternal serum endocan were statisticallysignificantly higher in the preeclampsia group compared to the control group (p=0.001, p=0.037, respectively).Conclusion: We found that ADMA and endocan molecules associated with endothelial dysfunction in the pathogenesis of preeclampsiasignificantly increased in maternal and umbilical cord serum

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31.
2. Nirupama R, Divyashree S, Janhavi P, Muthukumar SP, Ravindra PV. Preeclampsia: Pathophysiology and management. J Gynecol Obstet Hum Reprod 2021;50:101975.
3. Böger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 2003;4:1-3.
4. Guerby P, Tasta O, Swiader A, et al. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol 2021;40:101861.
5. Hentschke MR, Lucas LS, Mistry HD, Pinheiro da Costa BE, Poli-de-Figueiredo CE. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine 2015;74:152-6.
6. Leite AR, Borges-Canha M, Cardoso R, Neves JS, CastroFerreira R, Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology 2020;71:397-410.
7. Feng X, Liu Y, Zhang Y, et al. New views on endothelial dysfunction in gestational hypertension and potential therapy targets. Drug Discov Today 2021;26:1420-36.
8. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010;376:631-44.
9. Mauro AK, Khurshid N, Berdahl DM, et al. Cytokine concentrations direct endothelial function in pregnancy and preeclampsia. J Endocrinol 2021;248:107-17.
10. Adekola H, Romero R, Chaemsaithong P, et al. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med 2015;28:1621-32.
11. Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens 2016;38:137-42.
12. Cunningham FG. Hypertensive disorders. In: F. Gary Cunningham, Kenneth J. Leveno, Steven L. Bloom, et al. editors. Williams Obstetrics. 24th ed. New York: Mc Graw Hill; 2014. p. 728-79.
13. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998;77:808-13.
14. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GS. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993;342:242-3.
15. Böger RH, Diemert A, Schwedhelm E, Lüneburg N, Maas R, Hecher K. The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecol Obstet Invest 2010;69:1-13.
16. Yuan J, Wang X, Xie Y, et al. Circulating asymmetric dimethylarginine and the risk of preeclampsia: a meta-analysis based on 1338 participants. Oncotarget 2017;8:43944-52.
17. Meng W, Zhanashunbayaer, E L, Li R. Association between asymmetric dimethylarginine level and preeclampsia: a metaanalysis. Int J Clin Exp Med 2017;10:8720-7.
18. Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998;178:551-6.
19. Bian Z, Shixia C, Duan T. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia. PLoS One 2015;10:0124684.
20. Speer PD, Powers RW, Frank MP, Harger G, Markovic N, Roberts JM. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008;198:112.e1-7.
21. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511-7.
22. Albayrak M, Öncül M, Uludağ S, et al. Comparison of maternal serum and umbilical cord concentrations of nitric oxide and asymmetric-dimethyl-arginine in pre-eclamptic and uncomplicated pregnancies. J Exp Clin Med 2013;30:125-8.
23. Gumus E, Atalay MA, Cetinkaya Demir B, Sahin Gunes E. Possible role of asymmetric dimethylarginine (ADMA) in prediction of perinatal outcome in preeclampsia and fetal growth retardation related to preeclampsia. J Matern Fetal Neonatal Med 2016;29:3806-11.
24. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014;86:1213-20.
25. Lan X, Liu Z. Circulating endocan and preeclampsia: a metaanalysis. Biosci Rep 2020;40:BSR20193219.
26. Yuksel MA, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet 2015;292:69-73.
27. Chang X, Bian Y, Wu Y, Huang Y, Wang K, Duan T. Endocan of the maternal placenta tissue is increased in pre-eclampsia. Int J Clin Exp Pathol 2015;8:14733-40.
28. Ovayolu A, Karaman E, Turgut A, Guler S, Bostancieri N. Maternal serum endothelial cell-specific molecule-1 level and its correlation with severity of early-onset preeclampsia. J Obstet Gynaecol 2020:1-6.
29. Lopes ACDS, Martins SR, Dusse LMS, Pinheiro MB, Alpoim PN. Are Endocan Plasma Levels Altered in Preeclampsia? Rev Bras Ginecol Obstet 2021;43:232-4.
30. Schuitemaker J, Woudenberg J, Wijbenga G, Scherjon S, van Pampus M, Faas M. PP077. New prognostic marker for the risk to develop early-onset preeclampsia. Pregnancy Hypertens 2013;3:95-6.
31. Szpera-Gozdziewicz A, Kosicka K, Gozdziewicz T, et al. Maternal Serum Endocan Concentration in Pregnancies Complicated by Intrauterine Growth Restriction. Reprod Sci 2019;26:370-6.
32. Aksoy M, Aksoy AN, Laloglu E, Dostbil A, Celik MG. Umbilical cord blood endocan levels according to the delivery mode. Clin Exp Obstet Gynecol 2015;42:776-80.

APA	INANDİKLİOGLU N, BASER E, KİRMİZİ D (2021). Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. , 308 - 312. 10.4274/haseki.galenos.2021.7101
Chicago	INANDİKLİOGLU Nihal,BASER Emre,KİRMİZİ Demet Aydogan Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. (2021): 308 - 312. 10.4274/haseki.galenos.2021.7101
MLA	INANDİKLİOGLU Nihal,BASER Emre,KİRMİZİ Demet Aydogan Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. , 2021, ss.308 - 312. 10.4274/haseki.galenos.2021.7101
AMA	INANDİKLİOGLU N,BASER E,KİRMİZİ D Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. . 2021; 308 - 312. 10.4274/haseki.galenos.2021.7101
Vancouver	INANDİKLİOGLU N,BASER E,KİRMİZİ D Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. . 2021; 308 - 312. 10.4274/haseki.galenos.2021.7101
IEEE	INANDİKLİOGLU N,BASER E,KİRMİZİ D "Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia." , ss.308 - 312, 2021. 10.4274/haseki.galenos.2021.7101
ISNAD	INANDİKLİOGLU, Nihal vd. "Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia". (2021), 308-312. https://doi.org/10.4274/haseki.galenos.2021.7101

APA	INANDİKLİOGLU N, BASER E, KİRMİZİ D (2021). Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. Haseki Tıp Bülteni, 59(4), 308 - 312. 10.4274/haseki.galenos.2021.7101
Chicago	INANDİKLİOGLU Nihal,BASER Emre,KİRMİZİ Demet Aydogan Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. Haseki Tıp Bülteni 59, no.4 (2021): 308 - 312. 10.4274/haseki.galenos.2021.7101
MLA	INANDİKLİOGLU Nihal,BASER Emre,KİRMİZİ Demet Aydogan Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. Haseki Tıp Bülteni, vol.59, no.4, 2021, ss.308 - 312. 10.4274/haseki.galenos.2021.7101
AMA	INANDİKLİOGLU N,BASER E,KİRMİZİ D Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. Haseki Tıp Bülteni. 2021; 59(4): 308 - 312. 10.4274/haseki.galenos.2021.7101
Vancouver	INANDİKLİOGLU N,BASER E,KİRMİZİ D Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia. Haseki Tıp Bülteni. 2021; 59(4): 308 - 312. 10.4274/haseki.galenos.2021.7101
IEEE	INANDİKLİOGLU N,BASER E,KİRMİZİ D "Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia." Haseki Tıp Bülteni, 59, ss.308 - 312, 2021. 10.4274/haseki.galenos.2021.7101
ISNAD	INANDİKLİOGLU, Nihal vd. "Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia". Haseki Tıp Bülteni 59/4 (2021), 308-312. https://doi.org/10.4274/haseki.galenos.2021.7101